Company profile

Ticker
VBIV
Exchange
CEO
Jeffrey R. Baxter
Employees
Location
Fiscal year end
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK

VBIV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

31 Jul 20
10 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Dec 19 Sep 19
Revenue 184K 415K 574K 647K
Net income -9.51M -8.36M -10.88M -16.16M
Diluted EPS -0.04 -0.05 -0.02 -0.15
Net profit margin -5170% -2014% -1895% -2498%
Operating income -8.14M -9.41M -10.17M -16.14M
Net change in cash 25.23M -8.41M -8.8M 22.94M
Cash on hand 61.03M 35.8M 44.21M 53.02M
Cost of revenue 2.06M 2.58M 2.59M 1.98M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 2.22M 3.36M 865K 548K
Net income -54.81M -63.6M -39M -23.21M
Diluted EPS -0.46 -0.97 -0.88 -0.77
Net profit margin -2468% -1896% -4508% -4234%
Operating income -52.4M -60.41M -37.28M -24.85M
Net change in cash -15.06M -8.42M 35.41M 19.81M
Cash on hand 44.21M 59.27M 67.69M 32.28M
Cost of revenue 7.9M 4.51M 5.19M 3.67M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
1 Jul 20 Beattie Nell Option (Right to Buy Common Shares) Common Shares Grant Aquire A No 2.94 170,100 500.09K 170,100
1 Jul 20 McNulty Christopher Option (Right to Buy Common Shares) Common Shares Grant Aquire A No 2.94 170,100 500.09K 170,100
1 Jul 20 Diaz-Mitoma Francisco Option (Right to Buy Common Shares) Common Shares Grant Aquire A No 2.99 167,150 499.78K 167,150
1 Jul 20 Baxter Jeff Option (Right to Buy Common Shares) Common Shares Grant Aquire A No 2.94 425,200 1.25M 425,200
1 Jul 20 Anderson David Evander Option (Right to Buy Common Shares) Common Shares Grant Aquire A No 2.94 170,100 500.09K 170,100
33.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 71 75 -5.3%
Opened positions 13 22 -40.9%
Closed positions 17 17
Increased positions 25 31 -19.4%
Reduced positions 18 8 +125.0%
13F shares
Current Prev Q Change
Total value 119.38M 144.54M -17.4%
Total shares 78.1M 75.41M +3.6%
Total puts 10.2K 0 NEW
Total calls 111.1K 6.7K +1558.2%
Total put/call ratio 0.1
Largest owners
Shares Value Change
Perceptive Advisors 45.95M $43.65M 0.0%
BLK BlackRock 11.68M $11.1M +13.0%
Vanguard 3.19M $3.03M +7.4%
Geode Capital Management 2.38M $2.26M -2.9%
STT State Street 2.36M $2.24M +15.1%
First Midwest Bank Trust Division 2.03M $1.93M +42.3%
NTRS Northern Trust 1.87M $1.77M +10.3%
Cambridge Investment Research Advisors 1.71M $1.62M -0.4%
GAM General American Investors 1.31M $1.24M 0.0%
Nuveen Asset Management 639.16K $607K +53.6%
Largest transactions
Shares Bought/sold Change
BLK BlackRock 11.68M +1.34M +13.0%
Altshuler Shaham 0 -917.66K EXIT
First Midwest Bank Trust Division 2.03M +604.05K +42.3%
PAM Premier Asset Management 411.06K +411.06K NEW
Renaissance Technologies 342.8K +342.8K NEW
BK Bank of New York Mellon 475.05K +312.96K +193.1%
STT State Street 2.36M +310K +15.1%
Susquehanna International 397.33K +259.2K +187.6%
Nuveen Asset Management 639.16K +223.12K +53.6%
Vanguard 3.19M +219.07K +7.4%

Financial report summary

?
Management Discussion
  • All dollar amounts stated below are in thousands, unless otherwise indicated.
  • Revenue for the year ended December 31, 2019 was $2,221 as compared to $3,355 for the year ended December 31, 2018. The revenue decreased by $1,134 or 34%, as a result of the license revenue earned as part of the License Agreement with Brii Bio in the year ended December 31, 2018 with no similar transaction in the year ended December 31, 2019, offset by increased R&D services revenue as part of the License Agreement with Brii Bio for the year ended December 31, 2019. The decrease in revenue was also due to decreased product sales in Europe in the year ended December 31, 2019 due to reduced named-patient sales.
  • Cost of revenues for the year ended December 31, 2019 was $7,904 as compared to $4,509 for the year ended December 31, 2018. The increase in the cost of revenues of $3,395, or 75%, was due to cost of revenue related to the License Agreement with Brii Bio during the year ended December 31, 2019 of $1,141, which did not occur during the year ended December 31, 2018; the net increase related to the reclassification of certain costs of revenues to G&A expenses during the year ended December 31, 2018, which were not as significant in the year ended December 31, 2019 of $372; and the re-commencement of manufacturing subsequent to the temporary closure of our manufacturing facility in Rehovot, Israel which occurred in the second quarter of 2019.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abroad, accessed, Accrued, agent, alteration, American, Ankura, anniversary, baseline, Baxter, BCF, beneficial, biomarker, breach, California, CCPA, chain, Christopher, collateral, comply, compromise, confidential, confidentiality, confirmed, consumer, copy, corruption, coverage, created, criminal, criteria, CurrentDevelopment, cyber, cybersecurity, destruction, difficulty, dispense, duly, earlier, encounter, equivalent, ExhibitNo, extinguishment, feature, formatted, frequency, furnish, furnished, gave, Guaranty, healthcare, hearing, herewith, HIPAA, HITECH, imposition, inadvertent, increasingly, INFORMATIONCONTAINED, Inline, Instance, intensity, Interactive, intrinsic, isolated, Jeffrey, knowingly, landscape, Laon, Linkbase, LLC, McNulty, monetary, monovalent, mouse, multiplied, necessitated, notification, owner, page, parallel, percent, personal, posture, prepayment, prescribe, prime, privacy, procedural, progression, ratio, readily, receipt, recruitment, redacted, redeemable, redeemed, refinanced, registrant, registrational, remediation, repay, request, satisfactory, Schema, sector, sensitive, signatory, signature, sophisticated, sophistication, store, succeed, suggest, sustain, Taxonomy, theft, thereunto, today, topline, tranche, transmit, Trust, trustee, Twine, unauthorized, undersigned, unredacted, vulnerable, XBRL
Removed: appointed, cap, designate, designee, filling, guaranteed, individual, initially, issue, LIBOR, manager, minimum, Ontario, protein, purification, reclassification, requirement, resigned, shareholder, significantly, unamortized, upstream